Search Results - "Prezotti, Alessandra N L"

Immunogenicity of Current and New Therapies for Hemophilia A by Prezotti, Alessandra N. L, Frade-Guanaes, Jéssica O, Yamaguti-Hayakawa, Gabriela G, Ozelo, Margareth C

“…Anti-drug antibody (ADA) development is a significant complication in the treatment of several conditions. For decades, the mainstay of hemophilia A treatment…”
Get full text

Incidence of Inhibitors in Previously Untreated Patients with Severe Hemophilia a Treated with Plasma-Derived Vs. Recombinant Factor VIII Concentrates: A Systematic Review and Meta-Analyses by Prezotti, Alessandra N L, Villaça, Paula Ribeiro, Rocha, Debora M C, Orletti, Maria P S V, Lourenço, Christiane, Yamaguti Hayakawa, Gabriela G, Ozelo, Margareth C

Get full text

Incidence of Inhibitors in a Previously Untreated Patients with Severe Hemophilia Α Cohort Treated with a Single Third-Generation Recombinant Factor VIII Concentrate by Prezotti, Alessandra N L, Cerqueira, Monica H, Renni, Marilia, Ferreira, Clarissa, Pinto, Ieda S., Roberti, Maria do Rosário, Ribeiro, Rosangela, Villaça, Paula Ribeiro, Orletti, Maria P S V, Costa-Lima, Carolina, Yamaguti-Hayakawa, Gabriela G, Medina, Samuel S, Ozelo, Margareth C

“…Introduction: One of the most important complications in the treatment of patients with hemophilia A is the formation of neutralizing antibodies (inhibitors)…”
Get full text

Evaluation of Predictors of Outcome in Immune Tolerance Induction Treatment of Hemophilia Α Patients with High-Responding Inhibitors by Prezotti, Alessandra N L, Ferreira, Clarissa, Oliveira, Luciana, Lorenzato, Claudia, Orletti, Maria P S V, Roberti, Maria do Rosario, Ribeiro, Rosangela, Villaca, Paula Ribeiro, Montalvão, Silmara Aparecida De Lima, Medina, Samuel S, Yamaguti Hayakawa, Gabriela G, Ozelo, Margareth C

“…Introduction: Inhibitor development remains a major complication for patients with hemophilia A. Inhibitors are alloantibodies that neutralize factor (F) VIII…”
Get full text

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study by Peyvandi, Flora, Bucciarelli, Paolo, Valsecchi, Carla, Boscarino, Marco, Palla, Roberta, Santagostino, Elena, El-Beshlawy, Amal, Elalfy, Mohsen Saleh, Ramanan, Vijay M., Eshghi, Peyman, Hanagavadi, Suresh, Karimi, Mehran, Ross, Cecil, Manglani, Mamta V, Young, Guy, Seth, Tulika, Apte, Shashikant, Nayak, Dinesh M, Mancuso, Maria Elisa, Mahlangu, Johnny, Santiago, Bonanad, Cerqueira, Monica H, Ewing, Nadia P, Male, Christoph, Owaidah, Tarek, Soto Arellano, Veronica, Majumdar, Suvankar, Simpson, Mindy, Thomas, Mathew, Zanon, Ezio, Manco-Johnson, Marilyn J, Martinez, Monica, Mazzucconi, Maria Gabriella, Neme, Daniela, Paredes-Aguilera, Rogelio Alejandro, Prezotti, Alessandra N L, Schmitt, Klaus, Zulfikar, Bulent, Mannucci, Pier Mannuccio, Rosendaal, Frits Richard

“…Background: A major complication in severe hemophilia A is the formation of persistent neutralizing antibodies against factor(F) VIII, inhibitors, which render…”
Get full text